United States Generic Drugs Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The U.S. generic drugs market stands as the largest single-country market globally within the broader North American pharmaceutical sector, valued at approximately $130.06 billion in 2025 with a projected compound annual growth rate of 4.46%. Generics play a critical role in the American healthcare ecosystem, representing roughly 90 percent of all prescriptions dispensed while accounting for approximately 20 percent of total prescription drug expenditure. This disproportionate impact on access and affordability has made generic pharmaceuticals a policy priority and an economic staple.

• •Generics account for approximately 90% of U.S. prescriptions but only about 20% of total drug spending, delivering significant cost savings to patients and payers.
• •The FDA's Abbreviated New Drug Application (ANDA) pathway is the primary regulatory mechanism enabling generic competition after brand-name patent expiry.
• •Patent cliffs, the simultaneous expiration of patents on multiple blockbuster drugs, periodically create large influxes of generic market opportunities.

The single most important growth catalyst is the ongoing patent expiration of high-volume brand-name drugs, which opens revenue opportunities for generic manufacturers willing to invest in ANDA filings. Additional tailwinds include sustained governmental and payer pressure to reduce healthcare spending, robust demand driven by chronic disease prevalence, and an aging U.S. population requiring more long-term medication. Regulatory reforms that have streamlined the FDA's ANDA review process have also helped accelerate the pace at which generics reach patients.

• •An estimated $200 billion-plus in brand-name drug sales are projected to face generic competition over the coming decade, creating a substantial pipeline of market opportunities.
• •The Inflation Reduction Act and ongoing policy discussions around drug pricing continue to reinforce structural demand for lower-cost generic alternatives.
• •Rising prevalence of chronic conditions such as diabetes, cardiovascular disease, and respiratory disorders drives sustained high-volume demand for established generic therapies.

Within the North American region, the United States dominates the generic drugs market, while Canada represents a smaller but stable secondary market with its own provincial formularies and tendering systems. Therapeutically, the U.S. generics market is concentrated in categories including central nervous system agents, cardiovascular medications, anti-infectives, oncology, and diabetes care. Biosimilars, lower-cost alternatives to biologic drugs, are increasingly recognized as a distinct and fast-growing sub-segment as key biologics lose patent protection.

• •North America, led by the United States, holds the largest regional share of the global generic drugs market.
• •The biosimilars segment is emerging as a high-growth sub-market, driven by patent expirations on high-revenue biologic drugs.
• •Top therapeutic categories for generic drug volume include antihypertensives, lipid-lowering agents, antidepressants, and antidiabetic medications.

What are the recent trends and outlook?

Looking forward, the U.S. generic drugs market is expected to sustain steady growth through the mid-2030s, supported by continued patent expirations and structural demand for cost containment. The biosimilars opportunity represents a particularly significant expansion vector as more complex biologic therapies lose exclusivity. Digital supply chain technologies, advanced manufacturing processes, and evolving FDA policy will likely reshape operational dynamics, while potential drug pricing reform could further alter the competitive landscape.

• •The market is projected to reach approximately $180 billion to $200 billion globally by 2030, with the U.S. continuing to account for the largest national share.
• •Biosimilar approvals are accelerating, with dozens of products in development targeting high-revenue biologics across autoimmune, oncology, and metabolic disease indications.
• •Supply chain resilience and domestic manufacturing incentives, spurred by recent policy emphasis on reducing reliance on foreign drug manufacturing, are emerging as key strategic considerations.